Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled date : 2021 - 09 - 19 crawled time : 16:20 save search
AGM Selects Velodyne Lidar’s Alpha Prime Sensor for New Mobile Scanning System
Published: 2021-09-19 (Crawled : 16:20) - velodynelidar.com
VLDR | $1.26 2.38% 0
|
Electronic Technology
| Email alert
Add to watchlist
sensor mobile lidar primec
EverGROW COIN: The Hyper Deflationary Buy-Back Token Which Rewards Holder in USDT
Published: 2021-09-19 (Crawled : 16:20) - prnewswire.com
COIN S | $218.14 2.04% 2.0% 9.4M
|
| Email alert
Add to watchlist
15TH Annual "Evening Before" Benefiting MPTF
Published: 2021-09-19 (Crawled : 16:20) - prnewswire.com
TGT | $166.58 1.28% 0.0% 3.1M
|
Retail Trade
| Email alert
Add to watchlist
Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib as Monotherapy and in Combination with Cetuximab in Patients with KRAS G12C-Mutated Colorectal Cancer
Published: 2021-09-19 (Crawled : 16:20) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
| Email alert
Add to watchlist
positive therapy cancer colorectal cancer
New Data on RYBREVANT® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy
Published: 2021-09-19 (Crawled : 16:20) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
| Email alert
Add to watchlist
disease lung cancer therapy cancer
RYBREVANT® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
Published: 2021-09-19 (Crawled : 16:20) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
| Email alert
Add to watchlist
lung cancer cancer
Junshi Biosciences Announces Expansion of Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Post-Exposure Prophylaxis for COVID-19
Published: 2021-09-19 (Crawled : 16:20) - globenewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
| Email alert
Add to watchlist
covid expansion merge authorized emergency use authorization
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
Published: 2021-09-19 (Crawled : 16:20) - globenewswire.com
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
| Email alert
Add to watchlist
media cancer breast cancer her2+ her2- her2
Genmab and Seagen Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021
Published: 2021-09-19 (Crawled : 16:20) - globenewswire.com
GMAB | $28.32 -0.74% -0.74% 240K
|
Health Technology
| Email alert
Add to watchlist
SGEN | $228.74 0.1% 20M
|
Health Technology
| Email alert
Add to watchlist
treatment therapy results cancer
ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC
Published: 2021-09-19 (Crawled : 16:20) - globenewswire.com
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
| Email alert
Add to watchlist
treatment therapy
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.